Who are Ticagrelor plus aspirin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin and thienopyridine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-plus-aspirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ticagrelor plus aspirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ticagrelor plus aspirin (Ticagrelor plus aspirin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent combination. Area: Cardiovascular.

marketed Dual antiplatelet agent combination P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor plus aspirin (Ticagrelor plus aspirin) — Fujian Medical University. Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet activation and aggregation through different pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ticagrelor plus aspirin TARGET	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent combination class)

Associations for Establishment of Evidence in Interventions · 1 drug in this class
Fujian Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor plus aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-plus-aspirin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing